首页> 美国卫生研究院文献>Frontiers in Molecular Biosciences >The Impairment of TorsinAs Binding to and Interactions With Its Activator: An Atomistic Molecular Dynamics Study of Primary Dystonia
【2h】

The Impairment of TorsinAs Binding to and Interactions With Its Activator: An Atomistic Molecular Dynamics Study of Primary Dystonia

机译:TorsinA与其激活剂的结合及其相互作用的障碍:原发性肌张力障碍的原子分子动力学研究。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Primary dystonia's prolonged muscle contractions and the associated abnormal postures and twisting movements remain incurable. Genetic mutation/deletion of GAG from TorsonA's gene resulting in ΔE303 (which weakens the binding between TorsinA and its activator, such as LULL1) primarily cause this neurodegenerative disorder. We studied TorsinA-LULL1 (or TorsinAΔE303-LULL1) bindings and interactions. For the first time, we show the atomic details of TorsinA-LULL1 dynamic interactions and TorsinAΔE303-LULL1 dynamic interactions and their binding affinities. Our results show extensive effects of ΔE303 on TorsinAΔE303-LULL1 interactions, and suggest that the differences between TorsinA-LULL1 interactions and TorsinAΔE303-LULL1 interactions are non-subtle. ΔE303 significantly weakens TorsinAΔE303-LULL1's binding affinity. We present pieces of evidence proving that the effects of ΔE303 (on the differences between TorsinA-LULL1 interactions and TorsinAΔE303-LULL1 interactions) are more pronounced than previously suggested, and that the nanobody used for achieving the X-ray crystallization in the previous study attenuated the differences between TorsinA-LULL1 and TorsinAΔE303-LULL1 interactions. Our accounts of the dynamic interactions between “TorsinA and LULL1” and between “TorsinAΔE303 and LULL1” and the detailed effects of ΔE303 on TorsinA-/TorsinAΔE303-LULL1 build on previous findings and offer new insights for a better understanding of the molecular basis of Primary Dystonia. Our results have long-term potentials of guiding the development of medications for the disease.
机译:原发性肌张力障碍的长期肌肉收缩以及相关的异常姿势和扭曲运动仍然无法治愈。 GAG从TorsonA基因的遗传突变/缺失导致ΔE303(这削弱了TorsinA及其激活物(如LULL1)之间的结合),主要导致这种神经退行性疾病。我们研究了TorsinA-LULL1(或TorsinAΔE303-LULL1)的结合和相互作用。首次,我们显示了TorsinA-LULL1动态相互作用和TorsinAΔE303-LULL1动态相互作用及其结合亲和力的原子细节。我们的结果显示了ΔE303对TorsinAΔE303-LULL1相互作用的广泛影响,并表明TorsinA-LULL1相互作用与TorsinAΔE303-LULL1相互作用之间的差异不明显。 ΔE303显着削弱TorsinAΔE303-LULL1的结合亲和力。我们提供的证据证明,ΔE303(对TorsinA-LULL1相互作用和TorsinAΔE303-LULL1相互作用之间的差异的影响)比以前建议的更为明显,并且先前研究中用于实现X射线结晶的纳米抗体减弱了TorsinA-LULL1和TorsinAΔE303-LULL1相互作用之间的差异。我们对“ TorsinA和LULL1”之间以及“TorsinAΔE303和LULL1”之间的动态相互作用以及ΔE303对TorsinA- /TorsinAΔE303-LULL1的详细影响的解释建立在先前的发现基础之上,并提供了新的见解,可以更好地理解原代的分子基础。肌张力障碍。我们的结果具有指导该疾病药物开发的长期潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号